Tibet Rhodiola Pharmaceutical Holding Co. Financials

Market Capitalization CN¥11.85 Billion as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE	11.79
Forward PE	8.84
Price to Sales TTM	CN¥4.21
Price to Book MRQ	CN¥2.89
Enterprise to Revenue	3.30
Enterprise to EBITDA	10.39

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	35.80%
Operating Margin	34.95%
Return on Assets TTM	9.93%
Return on Equity TTM	25.86%

Income Statement

Revenue TTM	CN¥2,814,600,960
Revenue per Share TTM	CN¥8.74
Quarterly Revenue Growth	1.10%
Gross Profit TTM	CN¥2,651,552,000
EBITDA	CN¥1,128,244,199
Net Income to Common TTM	CN¥1,007,649,536
Diluted EPS TTM	CN¥3.12
Quarterly Earnings Growth YoY	-13.90%

Balance Sheet

Total Cash MRQ	CN¥3,126,354,688
Total Cash per Share MRQ	CN¥9.70
Total Debt MRQ	CN¥
Total Debt to Equity MRQ	12.50
Current Ratio MRQ	3.86
Book Value per Share MRQ	CN¥12.72

Cash Flow

Operating Cash Flow TTM	CN¥868,422,976
Levered Free Cash Flow TTM	CN¥374,022,464

600211 Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	322,319,196
Float Shares	124,034,873
Avg 10 Volume	2,284,083
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	60.70%
% Held by Institutions	2.55%

Stock Price Summary

Beta	1.10
Fifty Two Week Low	CN¥31.23
Fifty Two Week High	CN¥45.12
Fifty Two Week Change	13.81%
Day 50 MA	CN¥36.43
Day 200 MA	CN¥37.11

Dividends and Splits

Forward Annual Dividend Rate	CN¥2.91
Forward Annual Dividend Yield	7.92%
Trailing Annual Dividend Rate	CN¥0.73
Trailing Annual Dividend Yield	1.98%
Payout Ratio	57.38%
Dividend Date
Ex Dividend Date	2025-04-22
Last Split Factor
Last Split Date	2020-04-17